Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Glucagon-like peptide-1(9-36) inhibits chemokine-induced migration of human CD4-positive lymphocytes.

Liberman A, Esser M, Marx N, Burgmaier M.

PLoS One. 2013;8(3):e58445. doi: 10.1371/journal.pone.0058445. Epub 2013 Mar 4. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/cdb46efb-fa7c-4507-93e9-eb739804ed8f.

2.

Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes.

Marx N, Burgmaier M, Heinz P, Ostertag M, Hausauer A, Bach H, Durst R, Hombach V, Walcher D.

Cell Mol Life Sci. 2010 Oct;67(20):3549-55. doi: 10.1007/s00018-010-0396-5. Epub 2010 May 21.

PMID:
20495843
3.

Ivabradine reduces chemokine-induced CD4-positive lymphocyte migration.

Walcher T, Bernhardt P, Vasic D, Bach H, Durst R, Rottbauer W, Walcher D.

Mediators Inflamm. 2010;2010:751313. doi: 10.1155/2010/751313. Epub 2010 Dec 5.

4.

LXR activation inhibits chemokine-induced CD4-positive lymphocyte migration.

Walcher D, Vasic D, Heinz P, Bach H, Durst R, Hausauer A, Hombach V, Marx N.

Basic Res Cardiol. 2010 Jul;105(4):487-94. doi: 10.1007/s00395-010-0092-5. Epub 2010 Apr 3.

PMID:
20364260
5.

Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma.

Walcher D, Hess K, Heinz P, Petscher K, Vasic D, Kintscher U, Clemenz M, Hartge M, Raps K, Hombach V, Marx N.

Hypertension. 2008 Feb;51(2):259-66. Epub 2007 Dec 24.

6.

Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.

Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH.

Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1407-14. doi: 10.1161/ATVBAHA.110.206425. Epub 2010 May 6.

7.

Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.

Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS.

Regul Pept. 2012 Nov 10;179(1-3):91-100. doi: 10.1016/j.regpep.2012.08.016. Epub 2012 Sep 15.

PMID:
22989472
8.

Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.

Sangle GV, Lauffer LM, Grieco A, Trivedi S, Iakoubov R, Brubaker PL.

Endocrinology. 2012 Feb;153(2):564-73. doi: 10.1210/en.2011-1732. Epub 2011 Dec 20.

PMID:
22186413
9.

The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.

Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T.

Breast Cancer Res Treat. 2012 Apr;132(2):449-61. doi: 10.1007/s10549-011-1585-0. Epub 2011 Jun 3.

PMID:
21638053
10.

Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.

Vittone F, Liberman A, Vasic D, Ostertag R, Esser M, Walcher D, Ludwig A, Marx N, Burgmaier M.

Diabetologia. 2012 Aug;55(8):2267-75. doi: 10.1007/s00125-012-2582-5. Epub 2012 May 18.

PMID:
22648661
11.

DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway.

Dai Y, Dai D, Wang X, Ding Z, Mehta JL.

Cardiovasc Drugs Ther. 2014 Oct;28(5):425-32. doi: 10.1007/s10557-014-6539-4.

PMID:
25022544
12.

Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.

Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y.

Hypertension. 2012 Sep;60(3):833-41. doi: 10.1161/HYPERTENSIONAHA.112.195115. Epub 2012 Aug 6.

13.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Morales J.

Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508. Erratum in: Postgrad Med. 2012 Jan;124(1):177-8.

PMID:
22104467
14.

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.

Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jetté L, Benquet C, Drucker DJ.

Diabetes. 2003 Mar;52(3):751-9.

15.

Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.

Green BD, Gault VA, Mooney MH, Irwin N, Bailey CJ, Harriott P, Greer B, Flatt PR, O'Harte FP.

J Mol Endocrinol. 2003 Dec;31(3):529-40.

PMID:
14664713
16.

Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.

Katagiri D, Hamasaki Y, Doi K, Okamoto K, Negishi K, Nangaku M, Noiri E.

J Am Soc Nephrol. 2013 Dec;24(12):2034-43. doi: 10.1681/ASN.2013020134. Epub 2013 Oct 3.

17.

Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor.

Yusta B, Somwar R, Wang F, Munroe D, Grinstein S, Klip A, Drucker DJ.

J Biol Chem. 1999 Oct 22;274(43):30459-67.

18.

Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation.

Koole C, Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM.

J Biol Chem. 2012 Feb 3;287(6):3642-58. doi: 10.1074/jbc.M111.309328. Epub 2011 Dec 6.

19.

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.

Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS.

J Pharmacol Exp Ther. 2012 Feb;340(2):248-55. doi: 10.1124/jpet.111.186866. Epub 2011 Oct 24.

20.

Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.

Higashijima Y, Tanaka T, Yamaguchi J, Tanaka S, Nangaku M.

Am J Physiol Renal Physiol. 2015 Apr 15;308(8):F878-87. doi: 10.1152/ajprenal.00590.2014. Epub 2015 Feb 4.

Supplemental Content

Support Center